🇺🇸 FDA
Patent

US 9789162

Systemic and local ex vivo gene therapy of the skeleton

granted A61KA61K35/28A61K38/1858

Quick answer

US patent 9789162 (Systemic and local ex vivo gene therapy of the skeleton) held by The United States of America as represented by the Department of Veteran Affairs expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Department of Veteran Affairs
Grant date
Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K35/28, A61K38/1858, A61K47/548, A61K47/62